论文部分内容阅读
目的 探讨超声双重造影对预测及评判胃癌伴肝转移新辅助化疗患者疗效的应用价值.方法 胃癌伴肝转移新辅助化疗患者82例,根据病情分为有效组(62例)与进展组(20例),对比两组化疗前后超声双重造影参数,统计术后病理组织微血管密度(MVD),分析造影参数与MVD的相关性.结果 治疗后3个周期峰值强度(PI)显著低于治疗前,开始增强时间(RT)、到达峰值时间(TTP)显著高于治疗前(P＜0.05);有效组PI显著低于进展组,RT、TTP均高于对照组(P＜0.05);MVD(68.23±15.21)条/200倍视野显著低于进展组(75.55±10.61)条(P=0.017),PI与MVD呈正相关,RT、TTP与MVD呈负相关.结论 超声双重造影参数、PI能有效预测与评判胃癌伴肝转移新辅助化疗效果,且敏感性较高.“,”Objective To investigate the application value of double contrast ultrasonography in the evaluation of neoadjuvant chemotherapy for gastric cancer with liver metastasis.Methods A total of 82 patients with gastric cancer with liver metastasis and neoadjuvant chemotherapy were selected,who were divided into effective group (n =62) and progression group (n =20) according to the disease condition.The ultrasound double contrast parameters were compared between the two groups before and after chemotherapy.The microvessel density (MVD) was measured by immunohistochemical staining after operation.Then analyze the correlation between ultrasound double contrast parameters and MVD.Results The peak intensity (PI) of the 3 cycles after treatment was significantly lower than that before treatment,the initial enhancement time (RT) and the peak arrival time (TIP) were significantly higher than those before treatment (P＜0.05).After 3 cycles,the PI in the effective group was significantly lower than that in the progressive group,and the RT and TIP levels were higher than those in the control group (P＜0.05).The MVD (68.23 ±15.21) /200 times visual field I in the observation group was significantly lower than the control group (75.55 ± 10.61).The difference was statistically significant (t=2.393,P=0.017).PI was positively correlated with MVD,while RT and TTP were negatively correlated with MVD.Conclusion Ultrasound double contrast can effectively predict and evaluate the effect of neoadjuvant chemotherapy for gastric cancer with liver metastasis.PI can effectively predict the efficacy of neoadjuvant chemotherapy for gastric cancer with liver metastasis,and has high sensitivity.